Please login to the form below

Not currently logged in
Email:
Password:

Aspen

This page shows the latest Aspen news and features for those working in and with pharma, biotech and healthcare.

BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial

BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial

As evidenced in ALPINE and ASPEN, our head-to-head trials of Brukinsa against the first-generation BTK inhibitor [Imbruvica], this potentially best-in-class molecule can provide meaningful responses and

Latest news

More from news
Approximately 9 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Strengthening business competition and reducing anti-competitive practices Strengthening business competition and reducing anti-competitive practices

    based on the allegation that Aspen had paid these competitors to not enter the market. ... In a landmark move, and as the direct product of the investigation, Aspen approached the CMA with an unprecedented settlement offer.

  • A new EU in the making, what lies ahead for pharma? A new EU in the making, what lies ahead for pharma?

    She has been creative in the way she pushed the boundaries of the treaties with, for example, the pricing investigation over Aspen Pharma.

  • Deal Watch October 2016 Deal Watch October 2016

    $330m. Neurology 2016. Aspen. 5 anesthetics. $770m royalties. $592m. 1.3. Neurology 2014.

  • Deal Watch September 2016 Deal Watch September 2016

    Reflecting a long standing business relationship, Aspen paid GSK £180m to acquire Ultiva, Nimbex, Tracrium, Mivacron and Anectinein, plus up to £100m in milestone payments. ... 500. GSK / Aspen. Asset acquisition. Sale of anaesthetic drugs [Ultiva,

  • Deal Watch June 2016 Deal Watch June 2016

    Meanwhile AstraZeneca has out-licensed ex-US rights to a portfolio of seven anaesthetics to Aspen. ... Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

  • Competition from within

    Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘BRIC’ markets (Brazil,

  • Compliance Hub Ltd

    Address:. Aspen Farm. Sheep Lane Woburn. Bedfordshire. MK17 9HD. UK.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...